NMPA published 5 medical devices final guidelines on April 30, 2026. They are aimed to facilitate manufacturers with clarity in clinical evaluation requirements. All five guidance documents are directed at Class III devices, which is the fundamental reason why the NMPA imposes strict requirements on clinical trials or same-type clinical evaluations.
- Clinical Evaluation Guideline on Spring Coils System through Same-type Comparison
- Clinical Trial Guideline on Inferior Vena Cava Filters
- Clinical Trial Guideline on Coronary Modified Balloons
- Clinical Trial Guideline on Intracranial Thrombectomy Stents
- Clinical Evaluation Guideline on Single-Use Hemodialyzers
Why Overseas Manufacturers Should Pay Close Attention
For overseas manufacturers, if existing global clinical data deviates from the new Chinese criteria for effectiveness endpoints, they may face demands for supplementary clinical trials or extensive retrospective data analysis during registration or renewal. Specifically for legacy models NMPA approved years ago, manufacturers must prove during the 5-year renewal that their existing clinical evidence still meets the stricter performance benchmarks defined in these new guidelines.
Spring coil systems (detachable coils) have long been dominated by international giants such as Stryker, Medtronic, MicroVention (Terumo), and Johnson & Johnson, with high technical barriers and a large import share in the Chinese market. The NMPA’s new same-type clinical evaluation guideline for spring coils means that the products’ registration requirements are aligning with international standards.
Inferior vena cava (IVC) filters are dominated by overseas players including Boston Scientific, BD (Bard), Cook Medical, and Cordis. These are Class III high-risk devices with well-known long-term safety concerns (e.g., migration, fracture, thrombosis). The new clinical trial guideline will impose stricter requirements on study endpoints, patient follow-up, and retrieval protocols.
The market of Coronary Modified Balloons is largely led by multinational giants such as Boston Scientific (Cutting Balloon), Medtronic, and Abbott. As cardiovascular interventions trend toward “leaving nothing behind” (intervention without implantation), modified balloons—such as cutting and scoring balloons—have become indispensable for treating complex calcified lesions. The new NMPA clinical trial guideline imposes clearer requirements on clinical endpoint selection, control group settings, and subgroup analyses for complex lesions.
Intracranial thrombectomy stents – a key device for acute ischemic stroke – are primarily supplied by Stryker (Trevo), Medtronic (Solitaire), Cerenovus, and Acandis. The Chinese market has seen rapid growth and increasing local competition (e.g., MicroPort, Neuracle). The new clinical trial guideline will directly impact how foreign manufacturers design registration studies for new products or extensions, and may require additional clinical evidence for already-approved devices during the 5-year renewal cycle.
The hemodialysis sector has long been dominated by international brands like Fresenius Medical Care, Baxter (Gambro), Nipro, and B. Braun. This guideline aims to refine the comparison standards for critical performance metrics, including membrane biocompatibility and solute clearance stability. With the rapid rise of China’s domestic dialysis industry, the NMPA’s heightened supervision means foreign players must provide more exhaustive comparison reports.
China Med Device, LLC has test engineers at NMPA testing centers, and seasoned clinical and regulatory staff to help you shorten your renewal or new approval time. info@ChinaMedDevice.com